Bone Marrow Organoid Generation from iPSCs
Solution Overview
Problem
Current in vitro models of bone and bone marrow lack the architectural and cellular diversity to effectively model bone marrow disorders, including blood malignancies, due to their minimal representation of specialist lineages and unique tissue organization.
Innovation Solution
A method for generating bone marrow organoids from pluripotent stem cells involves driving induced pluripotent stem cells to form mesodermal aggregates, inducing vascular and hematopoietic commitment, and embedding these aggregates in a hydrogel with a specific cytokine cocktail to form physiologically accurate bone marrow organoids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If current in vitro models use chips containing individual cell lineages or co-cultures, then the models are simple to manufacture and maintain, but they lack architectural and cellular diversity to effectively model bone marrow disorders
Solution Approach 1:
The bone marrow is segmented into distinct functional niches (hematopoietic niche, stromal niche, vascular niche) and further divided into specific cell lineages (hematopoietic stem cells, progenitors, endothelial cells, stromal cells). This segmentation allows each component to be independently differentiated from iPSCs using specific cytokine cocktails (e.g., SCF/FLT3L for HSCs, VEGF for endothelial cells, BMP4 for stromal cells), then assembled into organoids that recapitulate the complex architecture while maintaining manufacturability through standardized differentiation protocols.
Solution Approach 2:
The invention creates composite tissue structures by combining multiple cell lineages (hematopoietic, stromal, endothelial, fibroblastic) within a single organoid system. These composite organoids are generated by co-culturing differentially differentiated cell populations in a shared hydrogel matrix, enabling the system to model the multi-lineage complexity of native bone marrow while providing a unified platform for disease modeling and drug screening.
2Ease of manufacture
If mouse models are used to model human hematopoiesis, then the models are easy to maintain and reproduce, but they fail to accurately reproduce human pathologies for many blood cancer types
Solution Approach 1:
The invention creates human-specific bone marrow organoids by differentiating human iPSCs into the requisite cell lineages and assembling them to replicate human bone marrow architecture and cellular interactions. This human-to-human copying approach, rather than using mouse models, enables accurate modeling of human blood cancers and pathologies while maintaining experimental reproducibility through the use of reproducible iPSC differentiation protocols and controlled organoid generation.
Solution Approach 2:
The invention changes the fundamental parameter of species origin from mouse to human by using human iPSCs as the starting material. This parameter change enables the models to accurately reflect human biology and pathology. The differentiation parameters (cytokine concentrations, culture conditions, timing) are optimized to generate authentic human cell lineages and tissue architecture, ensuring the models are both human-relevant and experimentally controllable.
3Loss of information
If cells isolated from patients with blood cancer are kept in culture, then the cells can be studied for mechanistic insights, but they are poorly viable following sampling once not supported by bone marrow niche
Solution Approach 1:
The bone marrow organoid serves as an intermediary system that provides the essential niche support (stromal cells, cytokines, architectural framework) that patient-derived blood cancer cells need to survive and proliferate in vitro. The organoid's stromal compartment and secreted factors act as mediators that maintain patient cell viability and functionality, enabling long-term culture and study of these cells without requiring their native bone marrow niche.
Solution Approach 2:
The bone marrow organoid system provides multiple functions simultaneously: it serves as a supportive niche for patient cell survival, a platform for disease modeling, and a system for drug screening. This multi-functionality allows patient cells to be maintained in culture while the same system is used to study mechanisms of disease and test therapies, eliminating the need for separate support systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The generated bone marrow organoids replicate the cellular, molecular, and architectural features of hematopoietic tissues, providing a transformative model for studying bone marrow function, blood production, blood cancers, and target screening.
Implementation Method 1
embedding the mesodermal aggregates in a hydrogel, and incubating the hydrogel in a sprouting medium
Data Source
AI summary
The invention relates to a method of generating bone marrow organoids from pluripotent stem cells wherein said method comprises: a) driving induced pluripotent stem cells (iPSCs) to form mesodermal aggregates; b) inducing vascular and hematopoietic commitment of the mesodermal aggregates by further culturing the mesodermal aggregates in medium, supplemented with recombinant BMP4, FGF2, VEGFA and SCF; c) embedding the mesodermal aggregates in a hydrogel, and incubating the hydrogel in a sprouting medium comprising: a media suitable for stem cell maintenance supplemented with cytokines for differentiation, to form bone marrow organoids; and optionally d) separating the bone marrow organoids from the hydrogel for further free culture.